The Global Health Body Sounds Alert Over Severe Lack of Obesity Jabs
Less than one in 10 patients that would benefit from GLP-1 drugs like Wegovy are able to get them, caution the World Health Organization as it publishes its first recommendations on the drugs.
With more than one billion people worldwide currently classified as obese, it is advocating for increased and just availability to GLP-1 medication.
According to forecasts, in excess of 2,000,000,000 could be living with obesity by 2030 without intervention.
"The latest guidelines recognises that excess weight is a long-term condition that can be managed with holistic and ongoing care," stated the agency's head Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and distribution challenges are key hurdles to broad availability to the jabs that can help people shift considerable body mass, explains the organization.
Skinny Jab Supply Crisis
Even under the current most favorable scenario, the production of these medications would only suffice for about 100 million people – fewer than 10% of the global need, according to the WHO.
The recommendation calls on countries and companies to increase access, through measures including patent sharing.
A patent on semaglutide – the core ingredient of a leading brand – is set to lapse in several countries in 2026.
How Obesity Injections Function
The injections imitate a biological compound to reduce digestion speed, curb appetite and boost satiety so people consume fewer calories.
People commonly begin shedding pounds after several weeks of beginning the once-weekly jabs.
Studies suggests users may put most of the weight back on a year later of stopping the medication, when their usual appetite return.
To be above a healthy weight increases your likelihood for developing health problems, such as diabetes, heart disease, stroke, and certain cancers.
Excess weight affects individuals in countries worldwide and was responsible for millions of deaths worldwide in 2024, per the health agency.
